Kiniksa Pharmaceuticals International, plc (KNSA): Capital Expenditures
$1.57M
Year ended 2025-12-31
$1.63M
Trailing 12 months to 2026-03-31
+146.3%
3-year compound annual growth
+40.8%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.57M | +466.1% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $277.0K | +113.1% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $130.0K | +23.8% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $105.0K | -74.7% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $415.0K | +46.6% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $283.0K | -91.2% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $3.20M | -39.5% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $5.29M | n/m | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $69.0K | n/a | 2019-03-12, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.57M | +466.1% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $6.00M | -14.3% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.34M | +84.6% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $480.0K | +77.8% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $34.88M | -15.0% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $15.33M | +44.2% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $13.80M | -39.7% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $214.0K | +375.6% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $12.28M | -50.9% |
Compare KNSA, RARE, SUPN, AXSM side by side · Screen every company in Pharmaceutical Preparations ↗